CN1446537A - 甲磺酸二氢麦角碱冻干粉针及其制备方法 - Google Patents
甲磺酸二氢麦角碱冻干粉针及其制备方法 Download PDFInfo
- Publication number
- CN1446537A CN1446537A CN 03108768 CN03108768A CN1446537A CN 1446537 A CN1446537 A CN 1446537A CN 03108768 CN03108768 CN 03108768 CN 03108768 A CN03108768 A CN 03108768A CN 1446537 A CN1446537 A CN 1446537A
- Authority
- CN
- China
- Prior art keywords
- injection
- parts
- dihydroergotoxine
- freeze
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 31
- 239000007924 injection Substances 0.000 title claims abstract description 31
- 239000000843 powder Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- CRFFPDBJLGAGQL-UHFFFAOYSA-N 2-azaniumyl-3-[4-(trifluoromethyl)phenyl]propanoate Chemical compound OC(=O)C(N)CC1=CC=C(C(F)(F)F)C=C1 CRFFPDBJLGAGQL-UHFFFAOYSA-N 0.000 title 1
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000008215 water for injection Substances 0.000 claims abstract description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 11
- 229930195725 Mannitol Natural products 0.000 claims abstract description 11
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000008101 lactose Substances 0.000 claims abstract description 11
- 239000000594 mannitol Substances 0.000 claims abstract description 11
- 235000010355 mannitol Nutrition 0.000 claims abstract description 11
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 11
- 239000011975 tartaric acid Substances 0.000 claims abstract description 11
- 229920002307 Dextran Polymers 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 238000004108 freeze drying Methods 0.000 claims abstract description 7
- 239000012982 microporous membrane Substances 0.000 claims abstract description 7
- 238000005303 weighing Methods 0.000 claims abstract description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 19
- ADYPXRFPBQGGAH-WVVAGBSPSA-N dihydroergotoxine Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-WVVAGBSPSA-N 0.000 claims description 9
- 229940120500 dihydroergotoxine Drugs 0.000 claims description 9
- 238000007689 inspection Methods 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 239000003643 water by type Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 20
- 229910052799 carbon Inorganic materials 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 238000001035 drying Methods 0.000 abstract description 2
- 238000004806 packaging method and process Methods 0.000 abstract 2
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 206010018910 Haemolysis Diseases 0.000 description 8
- 230000008588 hemolysis Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229960002802 bromocriptine Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229940000596 parlodel Drugs 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 2
- 241000239222 Tachypleus Species 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 229950010031 beta-ergocryptine Drugs 0.000 description 2
- YYWXOXLDOMRDHW-UHFFFAOYSA-N beta-ergocryptine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)C(C)CC)C(C)C)C2)=C3C2=CNC3=C1 YYWXOXLDOMRDHW-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- YYWXOXLDOMRDHW-SGVWFJRMSA-N β-ergocryptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)[C@@H](C)CC)C(C)C)C2)=C3C2=CNC3=C1 YYWXOXLDOMRDHW-SGVWFJRMSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- UJYGDMFEEDNVBF-UHFFFAOYSA-N Ergocorninine Natural products C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)C(C)C)C(C)C)C2)=C3C2=CNC3=C1 UJYGDMFEEDNVBF-UHFFFAOYSA-N 0.000 description 1
- -1 Ergota spit of fland Chemical compound 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000001407 Vascular Headaches Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 1
- 229940069063 dihydro-beta-ergocryptine Drugs 0.000 description 1
- SEALOBQTUQIVGU-QNIJNHAOSA-N dihydroergocornine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 SEALOBQTUQIVGU-QNIJNHAOSA-N 0.000 description 1
- 229960004290 dihydroergocornine Drugs 0.000 description 1
- 229960002032 dihydroergocryptine Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- SBFXHXZNBNFPHV-PXXBSISHSA-N epicriptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)[C@H](C)CC)C(C)C)=C3C2=CNC3=C1 SBFXHXZNBNFPHV-PXXBSISHSA-N 0.000 description 1
- XQUUDUKVJKNJNP-OGGGUQDZSA-N ergocornine Chemical compound C([C@H]1N(C)C2)C([C]34)=CN=C4C=CC=C3C1=C[C@H]2C(=O)N[C@@]1(C(C)C)C(=O)N2[C@@H](C(C)C)C(=O)N3CCC[C@H]3[C@]2(O)O1 XQUUDUKVJKNJNP-OGGGUQDZSA-N 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种甲磺酸二氢麦角碱冻干粉针及其制备方法,它按重量份数比由0.025~0.035份注射用甲磺酸二氢麦角碱、2~10份2%~10%甘露醇或2~10份右旋糖苷或2~10份乳糖或2~10份酒石酸及89~97份注射用水组成。按比例称取各组份,加注射用水溶解;加入针用活性炭或不加活性炭,在水浴上加热至60℃,保温30分钟,温度控制在10℃~60℃之间,再加入注射用水至组分比例;用微孔滤膜过滤;合格后分装,在真空条件下冷冻干燥。本剂型的药品含水量低,同时干燥在真空中进行,故不易氧化,保持药品组分的稳定性,进而使药品有效期延长。本品所加的辅料不影响药物疗效,因制成干粉包装可简易,运输方便,节约包装运输成本。
Description
技术领域 本发明涉及一种临床上主要用于改善与老年化有关的精神退化的症状和体症的药物,具体说是一种甲磺酸二氢麦角碱冻干粉针及其制备方法。
背景技术 甲磺酸二氢麦角碱是一种由四种天然麦角碱组份氢化后组成的产物,麦角考宁、麦角汀、α-麦角隐亭和β-麦角隐亭组份比例为3∶3∶2∶1。甲磺酸二氢麦角碱的治疗作用(1)主要用于改善与老年化有关的精神退化的症状和体症。(2)急慢性脑血管病后遗症的功能、智力减退的症状。(3)轻中度血管性痴呆。(4)血管性头痛。
目前,我国有甲磺酸二氢麦角碱片剂和胶囊,注射剂只有进口的甲磺酸二氢麦角碱注射液其商品名为:斯托芬。由于甲磺酸二氢麦角碱针剂在水溶液中极易被氧化,α-麦角隐亭和β-麦角隐亭易相互转化,使其比例发生改变。见光后分解的更快,因此,其注射液存在着产品质量不稳定、有效期短、包装、运输、贮存等环节存在许多不便。另外在本药的生产中用高温灭菌,药物易受到破坏,不能保证产品质量。
发明内容 本发明的目的在于改变甲磺酸二氢麦角碱的现有剂型,制成甲磺酸二氢麦角碱冻干粉针,克服了甲磺酸二氢麦角碱注射液稳定性差、有效期短、包装、运输、贮存不方便的缺点,制成冻干粉针,为临床提供一种稳定性可靠、安全有效、使用方便的甲磺酸二氢麦角碱新剂型,并提供其制备方法。
本发明的技术方案如下:
本冻干粉针是以注射用甲磺酸二氢麦角碱为原料,添加辅料2%~10%甘露醇或右旋苷或乳糖或酒石酸为支撑剂和骨架。
本冻干粉针按重量份数比由0.025~0.035份注射用甲磺酸二氢麦角碱、2~10份2%~10%甘露醇或2~10份右旋糖苷或2~10份乳糖或2~10份酒石酸及89~97份注射用水组成。
本冻干粉针剂的优选方案为:按重量份数比由0.025~0.035份注射用甲磺酸二氢麦角碱、4~8份2%~10%甘露醇或4~8份右旋糖苷或4~8份乳糖或4~8份酒石酸及91~96份注射用水组成。
其制备方法为:1、按上述比例称取注射用甲磺酸二氢麦角碱、2%~10%甘露醇或右旋糖苷或乳糖或酒石酸。2、加注射用水溶解。3、按0.1%~0.5%(w/v)加入针用活性炭或不加活性碳,在水浴上加热至60℃,保温30分钟,温度控制在10℃~60℃之间,再加入注射用水至组分比例。4、用0.22μm微孔滤膜过滤。5、所得中间体进行pH值和含量测定的检查,当pH值为4.2~5.2时,含量合格后分装,在真空条件下冷冻干燥。
上述方法中在水浴上加热至60℃,保温30分钟,温度控制在30℃~60℃之间。
上述制备方法中如温度高则药物易分解。
本发明的优点在于:1、本剂型的药品含水量低,控制在3%以内,同时干燥在真空中进行,故不易氧化,保持药品组分的稳定性,可避免药品因高热分解变质,进而使药品有效期延长。2、本药品所加的辅料不影响药物疗效,经辅料干扰试验,辅料不干扰主要成分检出。本产品质地疏松,加水后迅速溶解恢复药原有的特性。3、加活性碳可除去热原,避免输液中可能发生的不良反应,使药物品质更可靠,并可同时脱色。4、因制成干粉包装可简易,运输方便,节约包装运输成本。5、储藏时间长方便药品的管理。
具体实施方式 实施例
1、制剂原料 甲磺酸二氢麦角碱每瓶0.25mg~0.35mg。按平均装量计算,含甲磺酸二氢麦角碱(总碱)应为标示量的90.0%~110.0%,其中含甲磺酸二氢麦角考宁(C31H41N5O5·CH4O3S)、甲磺酸二氢麦角汀(C35H41N5O5·CH4O3S)、甲磺酸二氢麦角隐亭(C32H43N5O5·CH4O3S)应分别为甲磺酸二氢麦角碱总量的30.0%~36.5%,甲磺酸二氢-α-麦角隐亭与甲磺酸二氢-β-麦角隐亭总量的比值为1.5~2.5∶1.0。
注射用甲磺酸二氢麦角碱来源于江苏省信诺医药对外贸易有限公司,甘露醇来源于青岛胶南明月海藻工业有限公司,右旋糖苷来源于山东临沂制药厂,乳糖来源于西安第四制药厂,酒石酸来源于西安制药厂五分厂。
2、制备方法
A、称取甲磺酸二氢麦角碱0.25g及甘露醇25g。加入800ml注射用水溶解。按0.1%~0.5%(w/v)加入针用活性炭,在水浴上加热至60℃,保温30分钟,再加入注射用水至1000ml。用0.22μm微孔滤膜过滤,所得中间体进行pH值和含量测定的检查,合格后。分装,在真空条件下冷冻干燥。
B、称取甲磺酸二氢麦角碱0.35g及右旋糖苷90g。加入800ml注射用水溶解。按0.1%~0.5%(w/v)加入针用活性炭,在水浴上加热至60℃,保温30分钟,再加入注射用水至1000ml。用0.22μm微孔滤膜过滤,所得中间体进行pH值和含量测定的检查,合格后。分装,在真空条件下冷冻干燥。
C、称取甲磺酸二氢麦角碱0.30g及乳糖60g。加入800ml注射用水溶解。按0.1%~0.5%(w/v)加入针用活性炭,在水浴上加热至60℃,保温30分钟,再加入注射用水至1000ml。用0.22μm微孔滤膜过滤,所得中间体进行pH值和含量测定的检查,合格后。分装,在真空条件下冷冻干燥。
D、称取甲磺酸二氢麦角碱0.32g及酒石酸70g。加入800ml注射用水溶解。按0.1%~0.5%(w/v)加入针用活性炭,在水浴上加热至60℃,保温30分钟,再加入注射用水至1000ml。用0.22μm微孔滤膜过滤,所得中间体进行pH值和含量测定的检查,合格后。分装,在真空条件下冷冻干燥。
本发明的药物作了如下安全性试验:
1、血管刺激性试验
取健康雄性家兔4只,体重2.2~2.4Kg,分成两组,每只家兔右耳为给药组,左耳为生理盐水对照组,每只家兔右耳静脉注射供试药品的给药剂量为0.12mg/kg,给药容量为2.0ml/kg;家兔左耳缘静脉注射等容量的生理盐水。每日一次,连续三日,然后观察动物耳部血管刺激反应症状,并取标本进行病理组织学检查。
试验结果 给药组、生理盐水对照组的家兔耳部血管均无充血,结节、水肿及组织变性或坏死等反应症状,病理学检查也无异常改变,表明供试品无明显血管刺激性,符合规定要求。
2、过敏试验
取健康豚鼠12只,雌雄兼用,雌无孕,健康,体重220~260g。按无菌操作,给药组每只动物均隔日腹腔注射供试品溶液0.5ml,共3次,阳性对照组每只动物隔日腹腔注射1%卵白蛋白0.5ml共3次;其中给药组的第一组于首次给药后14日静脉注射供试品2ml进行攻击,第二组于首次给药后21日同法攻击;阳性对照组的第一组于首次给药后14日静脉注射1%白蛋白2ml进行攻击,第二组于首次给药后21日同法攻击,观察攻击后动物的过敏反应症状。
试验结果 给药组动物在注射后均无竖毛、呼吸困难、痉挛、休克及死亡等过敏反应症状,而阳性对照组动物在注射后均有不同程度的竖毛、抓鼻、痉挛等过敏症状,表明供试药品无明显过敏性,符合规定要求。
3、溶血试验
取健康家兔1只,自心脏采血约5ml,置三角烧瓶中,除去纤维蛋白元,然后将血液移至刻度离心管内,加入生理盐水5ml,混匀后,离心5分钟(2000rpm)除去上清液,再加生理盐水混匀离心,反复洗3~5次至上清液呈无色透明为止。将所得红细胞用生理盐水稀释成2%(红细胞1.6ml加生理盐水80ml)混悬液备用.取7只试管,编号排列于试管架,按表1加入各种试液,第6管不加供试品溶液作为空白对照,第7管仍不加供试品溶液,并用蒸馏水代替生理盐水,作为溶血得阳性对照。将各管轻轻摇匀,在37℃恒温水浴保温,观察0.5、1、2、3小时,各管有无沉淀和细胞凝集溶血现象,结果如下表所示:
试管号 1 2 3 4 5 6 7
供试品(ml) 0.1 0.2 0.3 0.4 0.5
生理盐水(ml) 2.4 2.3 2.2 2.1 2.0 2.5 2.5(蒸馏水)
细胞悬液(ml) 2.5 2.5 2.5 2.5 2.5 2.5 2.5
0.5小时 - - - - - - ++
1小时 - - - - - - ++
2小时 - - - - - - ++
3小时 - - - - - - ++
(-)不溶血,(±)难以判断,(+)部分溶血,(++)全部溶血由表可见,体外溶血试验均未见溶血及血球凝集现象,与生理盐水组比较无明显差别,常规方法作红细胞镜检,未见红细胞破裂及形态异常。蒸馏水组则完全溶血,产生红色透明溶液。结果表明:本发明的药品无沉淀、细胞凝集和溶血现象。
4、细菌内毒素的测定
采用两个厂家鲎试剂,对本发明的药品连续三个批号进行了干扰试验,结果表明对鲎试剂试验无干扰作用,可进行细菌内毒素检查。
根据试验结果,确定本发明药品检查方法如下:取本品,依法检查(《中国药典》2000年版附录XIE)每1ml中含内毒素量应小于250EU。
Claims (4)
1、一种甲磺酸二氢麦角碱冻干粉针,其特征在于:它以注射用甲磺酸二氢麦角碱为原料,添加辅料2%~10%甘露醇或右旋苷或乳糖或酒石酸为支撑剂和骨架;本冻干粉针按重量份数比由0.025~0.035份注射用甲磺酸二氢麦角碱、2~10份2%~10%甘露醇或2~10份右旋糖苷或2~10份乳糖或2~10份酒石酸及89~97份注射用水组成。
2、根据权利要求1所述的甲磺酸二氢麦角碱冻干粉针,其特征在于:它的优选方案为:按重量份数比由0.025~0.035份注射用甲磺酸二氢麦角碱、4~8份2%~10%甘露醇或4~8份右旋糖苷或4~8份乳糖或4~8份酒石酸及91~96份注射用水组成。
3、一种甲磺酸二氢麦角碱冻干粉针的制备方法,其特征在于:它由如下步骤制成:(1)、按比例称取注射用甲磺酸二氢麦角碱、2%~10%甘露醇或右旋糖苷或乳糖或酒石酸;(2)、加注射用水溶解;(3)、按0.1%~0.5%(w/v)加入针用活性炭或不加活性碳,在水浴上加热至60℃,保温30分钟,温度控制在10℃~60℃之间,再加入注射用水至组分比例;(4)、用0.22μm微孔滤膜过滤;(5)、所得中间体进行pH值和含量测定的检查,当pH值为4.2~5.2时含量合格后分装,在真空条件下冷冻干燥。
4、根据权利要求3所述的甲磺酸二氢麦角碱冻干粉针的制备方法,其特征在于:它在水浴上加热至60℃,保温30分钟,温度控制在30℃~60℃之间。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03108768 CN1446537A (zh) | 2003-03-29 | 2003-03-29 | 甲磺酸二氢麦角碱冻干粉针及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03108768 CN1446537A (zh) | 2003-03-29 | 2003-03-29 | 甲磺酸二氢麦角碱冻干粉针及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1446537A true CN1446537A (zh) | 2003-10-08 |
Family
ID=28050235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03108768 Pending CN1446537A (zh) | 2003-03-29 | 2003-03-29 | 甲磺酸二氢麦角碱冻干粉针及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1446537A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1296045C (zh) * | 2005-03-15 | 2007-01-24 | 北京科信必成医药科技发展有限公司 | 二氢麦角碱及其衍生物的口腔崩解片及其制备工艺 |
CN100367961C (zh) * | 2005-09-30 | 2008-02-13 | 天津南开允公医药科技有限公司 | 盐酸替罗非班冻干粉针注射剂及其制备方法 |
-
2003
- 2003-03-29 CN CN 03108768 patent/CN1446537A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1296045C (zh) * | 2005-03-15 | 2007-01-24 | 北京科信必成医药科技发展有限公司 | 二氢麦角碱及其衍生物的口腔崩解片及其制备工艺 |
CN100367961C (zh) * | 2005-09-30 | 2008-02-13 | 天津南开允公医药科技有限公司 | 盐酸替罗非班冻干粉针注射剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017032275A1 (zh) | 一种羊依诺肝素钠及其制备方法与应用 | |
CN103211774B (zh) | 一种注射用甲磺酸加贝酯组合物及其制备方法 | |
DE4424935C1 (de) | Humanes virussicheres monomeres Immunglobulin A und Verfahren zu seiner Herstellung | |
Niyonzima et al. | Hypoglycaemic activity of Spathodea campanulata stem bark decoction in mice | |
CN100457098C (zh) | 甲磺酸萘莫司他冻干粉针剂及其制备方法 | |
CN1446537A (zh) | 甲磺酸二氢麦角碱冻干粉针及其制备方法 | |
CN102626409A (zh) | 一种含18种氨基酸的药物组合物 | |
JP5700763B2 (ja) | 抗アレルギー剤 | |
CN102973524A (zh) | 一种埃索美拉唑钠冻干粉针剂及其制备方法 | |
CN104161732B (zh) | 注射用奥美拉唑钠及其制备方法和用途 | |
CN112641777A (zh) | 麦角硫因类物质在制备防治缺血性脑卒中药物中的应用 | |
IE44448B1 (en) | Gonococcal pili processes for the preparation thereof and the use thereof | |
CN107058269B (zh) | 药用激肽原酶及其制备方法和应用 | |
CN1404827A (zh) | 硫普罗宁制剂 | |
WO2020029443A1 (zh) | 一种盐酸替罗非班注射液及其制备方法 | |
CN112057424B (zh) | 一种曲克芦丁冻干粉针剂及其制备方法 | |
Beard et al. | The p H stability range of the elementary bodies of vaccinia | |
CN107496349A (zh) | 一种塑料安瓿灌装的盐酸氨溴索注射液组合物及其制备方法 | |
Ogwutum et al. | In vitro investigation of the anti-sickling and erythrocyte membrane stabilizing potentials of Elaesis guineensis Jacq Flower | |
Ratsimamanga‐Urverg et al. | In vitro antimalarial activity, chloroquine potentiating effect and cytotoxicity of alkaloids of Hernandia voyronii Jum.(Hernandiaceae) | |
CN105535951A (zh) | 一种乌司他丁注射液及其制备方法 | |
US20100196510A1 (en) | Composition and treatment | |
US20220079999A1 (en) | Antivenom compositions and uses thereof | |
CN1218704C (zh) | 注射用藻酸双酯钠及其制备方法 | |
CN103575912A (zh) | 红花制剂中过敏原的检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |